GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (ASX:BLT) » Definitions » 14-Day RSI

Benitec Biopharma (ASX:BLT) 14-Day RSI : 50.00 (As of May. 21, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Benitec Biopharma 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-21), Benitec Biopharma's 14-Day RSI is 50.00.

The industry rank for Benitec Biopharma's 14-Day RSI or its related term are showing as below:

ASX:BLT's 14-Day RSI is ranked worse than
95.42% of 1572 companies
in the Biotechnology industry
Industry Median: 48.52 vs ASX:BLT: 50.00

Competitive Comparison of Benitec Biopharma's 14-Day RSI

For the Biotechnology subindustry, Benitec Biopharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's 14-Day RSI falls into.



Benitec Biopharma  (ASX:BLT) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Benitec Biopharma  (ASX:BLT) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Benitec Biopharma 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (ASX:BLT) Business Description

Traded in Other Exchanges
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

Benitec Biopharma (ASX:BLT) Headlines

From GuruFocus

John Rogers Comments on Blount Intl Inc.

By Holly LaFon Holly LaFon 01-22-2016

John Rogers Trims Stake in Blount International

By Kyle Ferguson Kyle Ferguson 04-18-2016

Blount International Inc. (BLT) CEO Joshua L Collins buys 5,000 Shares

By GuruFocus Research GuruFocus Editor 06-17-2010

Blount International Inc. (BLT) CEO International Inc Blount buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-01-2009

Jean-Marie Eveillard Sells More Blount International

By Holly LaFon Holly LaFon 10-09-2012

Olstein Strategic Opportunities Fund 2014 Investor Letter

By Canadian Value Canadian Value 04-01-2015

Ariel Fund Quarterly Commentary From John Rogers

By Holly LaFon Holly LaFon 01-21-2016

John Rogers Increases Stake in Blount International

By Tiziano Frateschi Tiziano Frateschi 04-13-2015